Since someone bought it up, I was actually wondering why a company like Cipla finds it so difficult to pass such inspections. Are they negligent, or are the inspections just extremely demanding? Or is there some other issue that I am not aware of?
Surely in the light of the importance of these inspections, the company should do everything it could to make sure it passed without issue?
Also, is this the reinspection (audit?) that is referred to in the earnings call quoted above? As in “So, up to FDA, like they might need to reinspect the plant”? If so, it seems that Umang Vohra was not expecting this?
| Subscribe To Our Free Newsletter |
